BamSEC and AlphaSense Join Forces
Learn More

Akebia Therapeutics Inc. – Material Contracts

NASDAQ: AKBA    
Share price (3/27/26): $1.34    
Market cap (3/27/26): $359 million
Search in Documents
Key Exhibits
External Links

Material Contracts Filter

EX-10.98
from 10-K 7 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Amendment #1 to License Agreement
12/34/56
EX-10.97
from 10-K 60 pages Article 1 Definitions
12/34/56
EX-10.96
from 10-K 68 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Asset Purchase Agreement Between Q32 Bio Inc. and Q32 Bio Operations Inc. and Akebia Therapeutics, Inc. Dated as of November 28, 2025
12/34/56
EX-10.91
from 10-K 6 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Amendment #1 to License Agreement
12/34/56
EX-10.45
from 10-K 7 pages Akebia Therapeutics, Inc. Stock Option Agreement for Officers 2023 Stock Incentive Plan
12/34/56
EX-10.44
from 10-K 8 pages Akebia Therapeutics, Inc. Restricted Stock Unit Agreement for Officers 2023 Stock Incentive Plan
12/34/56
EX-10.43
from 10-K 8 pages Akebia Therapeutics, Inc. Stock Option Agreement for Officers 2023 Stock Incentive Plan
12/34/56
EX-10.42
from 10-K 8 pages Akebia Therapeutics, Inc. Restricted Stock Unit Agreement for Officers 2023 Stock Incentive Plan
12/34/56
EX-10.16
from 10-K 10 pages Executive Severance Agreement
12/34/56
EX-10.14
from 10-K 11 pages Amended and Restated Executive Severance Agreement
12/34/56
EX-10.11
from 10-K 4 pages Akebia Therapeutics, Inc. Fifth Amended and Restated Non-Employee Director Compensation Program Effective January 26, 2026
12/34/56
EX-10.10
from 10-K 93 pages 180 Citypoint Waltham, Massachusetts Lease Dated January 26, 2026
12/34/56
EX-10.1
from 10-Q 3 pages Amendment #3 to Supply Agreement
12/34/56
EX-10.78
from 10-K 7 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Whitby Product Agreement
12/34/56
EX-10.18
from 10-K 4 pages Akebia Therapeutics, Inc. Fourth Amended and Restated Non-Employee Director Compensation Program Effective January 27, 2025
12/34/56
EX-10.5
from 10-Q 3 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Amendment #1 to Supply Agreement
12/34/56
EX-10.4
from 10-Q ~1 page Amendment #1 to License Agreement
12/34/56
EX-10.4
from 10-Q 16 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Termination and Settlement Agreement
12/34/56
EX-10.3
from 10-Q 4 pages Certain Identified Information Has Been Excluded From the Exhibit Because It Is Both (I) Not Material and (II) Is the Type of Information That the Registrant Treats as Private or Confidential. Double Asterisks Denote Omissions. Amendment #1 to the Second Amended and Restated License Agreement
12/34/56
EX-10.2
from 10-Q 2 pages Amendment #2 to Supply Agreement
12/34/56